Seelos Therapeutics Inc (NASDAQ:SEEL)’s traded shares stood at 0.63 million during the last session, with the company’s beta value hitting 1.87. At the close of trading, the stock’s price was $3.41, to imply an increase of 13.67% or $0.41 in intraday trading. The SEEL share’s 52-week high remains $848.64, putting it -24786.8% down since that peak but still an impressive 14.96% since price per share fell to its 52-week low of $2.90. The company has a valuation of $1.98M, with an average of 2.57 million shares in intraday trading volume over the past 10 days and average of 527.43K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Seelos Therapeutics Inc (SEEL), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give SEEL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Seelos Therapeutics Inc (NASDAQ:SEEL) trade information
After registering a 13.67% upside in the last session, Seelos Therapeutics Inc (SEEL) has traded red over the past five days. The 5-day price performance for the stock is -12.56%, and -7.86% over 30 days. With these gigs, the year-to-date price performance is -98.08%. Short interest in Seelos Therapeutics Inc (NASDAQ:SEEL) saw shorts transact 7305.0 shares and set a 0.03 days time to cover.
SEEL Dividends
Seelos Therapeutics Inc has its next earnings report out on 2024-Mar-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Seelos Therapeutics Inc (NASDAQ:SEEL)’s Major holders
Seelos Therapeutics Inc insiders hold 0.49% of total outstanding shares, with institutional holders owning 4.47% of the shares at 4.49% float percentage. In total, 4.47% institutions holds shares in the company.
